R&D Spotlight focusing on pipeline advances
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your AVCT notes
| R&D Spotlight focusing on pre | CISION® technology and pipeline advances |
| LONDON - Oct. 30, 2024 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful antitumor payloads directly to the tumor, is today hosting a live R&D Spotlight: "Next Generation of pre | CISION® Medicines" in London. |
Avacta's unique proprietary technology allows for targeted delivery of cytotoxic drugs (the "payload") in the tumor microenvironment (TME). The presentations will cover the Company's next generation of follow-on candidates with their unique features and patient populations.
| Avacta will highlight in this event the novel pre | CISION® candidates in the evolving pipeline, details of which were presented at the EORTC-NCI-AACR Triple Meeting in Barcelona last week and provide further detail on their properties and patient populations. |
Avacta's AVA6000, AVA6103, and AVA7100 programs are highly differentiated pipeline assets, addressing large markets. The presentation will also address these programs' near-term milestones.
Avacta will highlight the franchise it has developed in breast cancer and how these therapies in this indication will move forward.
The Company confirms that the process to divest the revenue-generating diagnostics division is ongoing and it continues to actively explore opportunities for a potential dual listing on NASDAQ. No additional financial information will be disclosed.
This event is open to both analysts and investors, further details are provided on the Company website and a recording of the event will be made available in due course.
| The pre | CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre | CISION® platform harnesses this tumor specific protease to cleave pre | CISION® peptide drug conjugates and pre | CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients. |
| About AVA6000: FAP-enabled doxorubicin | ||||
| AVA6103: FAP-enabled PDC targeting Topoisomerase I | ||||
| AVA6103 is a pre | CISION-enabled PDC comprised of the pre | CISION peptide linked to exatecan, the most potent topoisomerase I inhibitor in clinical development. Exatecan has demonstrated clinical activity in breast, gastric, lung and pancreatic cancers; however, it is associated with severe dose-limiting toxicities and a short half-life in patients that led to discontinuation of its monotherapy development. AVA6103 is designed to enable patients to obtain the therapeutic benefit associated with exatecan, while limiting the systemic exposure associated with its poor tolerability. | ||
| AVA7100: pre | CISION® FAP Affimer Drug Conjugate (AffDC) | |||
| AVA7100 is a pre | CISION®-enabled Affimer® drug conjugate, a new class of therapies being developed by Avacta with potential applications in a variety of cancer types, including those with lower levels of FAP in the tumor. Affimer® molecules are small proteins that are engineered to bind to a target molecule in the same way that an antibody does, but with several advantages, including smaller molecule size and a broad range of binding affinity. AVA7100 consists of a novel FAP-Affimer conjugated to a pre | CISION®-peptide linker with multiple options for the payload. | ||
About Avacta Group plc - https://avacta.com/
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.